Dual-target neoadjuvant therapy with trastuzumab and pertuzumab blocked homodimer and heterodimer active model of HER-2, blocking the downstream signal transduction and showing promising efficacy against HER-2 positive breast cancer (17–21). The gene discussed is ERBB2; the disease is breast carcinoma.